OABI (OmniAb) Dividend Payout Ratio : 0.00 (As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is OmniAb Dividend Payout Ratio?

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. OmniAb's Dividend Payout Ratio for the months ended in Mar. 2025 was 0.00.

The historical rank and industry rank for OmniAb's Dividend Payout Ratio or its related term are showing as below:

OABI's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.47
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2025-07-14), the Dividend Yield % of OmniAb is 0.00%.

OmniAb's Dividends per Share for the months ended in Mar. 2025 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

OmniAb Dividend Payout Ratio Historical Data

The historical data trend for OmniAb's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OmniAb Dividend Payout Ratio Chart

OmniAb Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dividend Payout Ratio

Get a 7-Day Free Trial

OmniAb Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Dividend Payout Ratio	Get a 7-Day Free Trial												-	-	-	-	-

Competitive Comparison of OmniAb's Dividend Payout Ratio

For the Biotechnology subindustry, OmniAb's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OmniAb's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OmniAb's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where OmniAb's Dividend Payout Ratio falls into.

Save Embed

;

Save Embed

;

OmniAb Dividend Payout Ratio Calculation

OmniAb's Dividend Payout Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2024 )	/	EPS without NRI (A: Dec. 2024 )
	=	0	/	-0.61
	=	N/A

OmniAb's Dividend Payout Ratio for the quarter that ended in Mar. 2025 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2025 )	/	EPS without NRI (Q: Mar. 2025 )
	=	0	/	-0.17
	=	N/A

OmniAb (NAS:OABI) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

OmniAb Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of OmniAb's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

OmniAb Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OmniAb Inc (NAS:OABI) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

5980 Horton Street, Suite 600, Emeryville, CA, USA, 94608

Website

https://www.omniab.com

OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.

Executives

Jennifer R. Cochran	director	C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121
Steven Love	director	C/O OMNIAB, INC., 5980 HORTON STREET, SUITE 600, EMERYVILLE CA 94608
John L Higgins	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Kurt A Gustafson	officer: EVP, Finance and CFO	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Matthew W Foehr	director, officer: President & CEO	11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
Charles S Berkman	officer: See Remarks	11085 NORTH TORREY PINES ROAD, SUITE 300, LA JOLLA CA 92037
Carolyn R Bertozzi	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Avista Capital Managing Member V, Llc	director, 10 percent owner	65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners V Gp, L.p.	director, 10 percent owner	65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners (offshore) V, L.p.	director, 10 percent owner	65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners V, L.p.	director, 10 percent owner	65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Thompson Dean	director, 10 percent owner	65 EAST 55TH STREET, 18TH FLOOR, C/O AVISTA CAPITAL PARTNERS, NEW YORK NY 10022
Avista Acquisition Lp Ii	director, 10 percent owner	C/O AVISTA CAPITAL HOLDINGS, LP, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Acquisition Gp Llc Ii	director, 10 percent owner	C/O AVISTA CAPITAL HOLDINGS, LP, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
David F Burgstahler	director, 10 percent owner	C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866